ASX Top gainers today

The following three ASX stocks are among top gainers today supported by improved investor sentiment and long-term earnings outlooks.

Reece Limited (ASX: REH) 

is among the top ASX gainers today as it has surged 10.53% at the time of writing and the company’s current market capitalisation is $9.68 billion.
The company in HY26 reported sales revenue of $4.6 billion which was 6% higher than the prior corresponding period due to branch network expansion and resilient customer demand while EBITDA reached $448 million and EBIT was $262 million.

A key recent development was the opening of 19 new branches in the United States and four new branches across ANZ while the company also invested significantly in digital capabilities and customer service initiatives to enhance its long-term competitive position.

Reece also showed confidence in its outlook through the completion of a $401 million share buyback program while retaining a strong balance sheet with $774 million of available liquidity and the financial capacity to invest throughout market cycles.

Management expects a gradual recovery across Australia and plans to expand further in the large US plumbing and HVAC market with support from its 2030 vision which focuses on operational excellence and profitable growth.

AUB Group Limited (ASX: AUB) 

is among the top ASX gainers today as the stock is up 7.73% at the time of writing while market capitalisation is $3.68 billion.
The company in 1H26 reported revenue of $759.5 million which was up 6.6% while underlying NPAT increased 13.9% to $90.4 million and underlying EPS rose 13.9% to 77.54 cents.

EBIT reached $257.5 million after a 12.8% increase and the EBIT margin improved by 190 basis points to 33.9% which reflects the strength of AUB's diversified insurance platform.
Recent progress was encouraging as AUB announced the acquisition of Prestige which is a major UK insurance broker and underwriting platform while also completing around 30 smaller equity investments during the half and expanding its international presence.

Management has upgraded FY26 underlying NPAT guidance to $220 million to $230 million which implies growth of 9.9% to 14.9% over FY25.

Cogstate Limited (ASX: CGS) 

is among the top ASX gainers today as the stock is up 7.14% at the time of writing as investors reacted positively to strong sales momentum and improved earnings visibility which lifted the company's market capitalisation to approximately $471.43 million.

The company in 1H26 reported revenue of US$26.9 million which was up 12% while Clinical Trials revenue increased 13% to US$25.7 million and EBITDA rose 5% to US$6.5 million despite temporary pressure on margins. Profit before tax improved 2% to US$5.3 million and NPAT climbed 16% to US$4.5 million.

Operational performance was supported by 133 active trials which increased 34% year-on-year alongside 42 new trial starts compared with 25 in the prior corresponding period while executed sales contracts reached US$41.7 million which marked the second-highest half-year result in the company's history.

The balance sheet closed the half with US$34.1 million in cash and no debt and management expects FY26 revenue to exceed FY25 with gross margins of 56-59% in 2H26 supported by a record sales pipeline and contracted future revenue of US$104.9 million including US$48.6 million already secured for FY26.

(Source: Company Announcements)